-
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2024 Earnings Call Transcript
25 Apr 2024 07:28 GMT
… The target disease is IgA nephropathy. We see deposition of … DNA. And the RNA treatment drugs utilizes this mechanism. This … modality. The RNA inhibitor of treatment drug, siRNA moves to the … would like to offer innovative pharmaceuticals, and this time we …
-
Calliditas Announces Open Label Extension Results for Budesonide (Nefecon) in IgA Nephropathy
24 Apr 2024 17:28 GMT
… irrespective of previous treatment regimen in the Phase 3 trial,” Renée Aguiar … by the US Food and Drug Administration (FDA) for proteinuria reduction in … . FDA Awards Full Approval to Budesonide (Tarpeyo) in Treatment of IgA Nephropathy. HCPLive …
-
Chronic kidney disease was essentially a death sentence before HIV treatment became widely...
24 Apr 2024 15:22 GMT
… a physical injury, certain medications, an infection or certain … condition called HIV-associated nephropathy. Wearne says this occurs … seen by a nephrologist. Treating stages one and two … drug. If it was an infection, you treat the infection. So, it [treatment …
-
Travere Therapeutics Says European Commission Approved Filspari To Treat IgA Nephropathy
24 Apr 2024 12:12 GMT
Travere Therapeutics, Inc., (TVTX) and CSL Vifor Wednesday said the European Commission has granted conditional marketing authorization for Filspari for the treatment of adults with primary IgA nephropathy (IgAN), a rare kidney disorder.
The European …
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
24 Apr 2024 11:45 GMT
… #47;2a clinical trial (NCT06209177) of … treatment for complement mediated kidney diseases such as immunoglobulin A nephropathy … Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable … develop and commercialize drug candidates, the …
-
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
24 Apr 2024 11:05 GMT
… IgA nephropathy (IgAN) and the only head-to-head trial in … treatment. Following the 110-week blinded treatment period, treatment with study medication … treat appropriately. Patients with advanced kidney disease, taking concomitant potassium-increasing drugs …
-
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
24 Apr 2024 09:44 GMT
… therapy for the treatment of IgA Nephropathy (IgAN) approved … the phase-III PROTECT trial
ST. GALLEN, Switzerland … ; said Prof. Dr. med. Jürgen Floege, Senior Professor … developing, manufacturing and marketing pharmaceutical products for precision healthcare …
-
Chugai Pharmaceutical : Q1 Results (Jan-Mar 2024)
24 Apr 2024 08:09 GMT
… NHI drug price revisions, and the market penetration of generic drugs, domestic … bispecific monoclonal antibody) increased.
Chugai Pharmaceutical Co., Ltd. (4519) CONSOLIDATED … mRNA RG6299 for the treatment of IgA nephropathy in February 2024.
Neuroscience …
-
Interim analysis of APPLAUSE-IgAN trial sheds positive light on Fabhalta for IgAN
23 Apr 2024 17:23 GMT
… III APPLAUSE-IgAN clinical trial. According to the analysis … with immunoglobulin A (IgA) nephropathy (IgAN) compared to placebo. … will become the first treatment for IgAN that specifically … with Chinook’s lead drug astrasentan hydrochloride. This acquisition …
-
AstraZeneca gets grant for inhibitors of complement factor d for treating disorders
23 Apr 2024 15:21 GMT
… : US11926617B2) discloses a method for treating disorders mediated by complement factor … a host in need of treatment. The compound can be selected … deposit disease, geographic atrophy, IgA nephropathy, lupus nephritis, myasthenia gravis, neuromyelitis …